key: cord-0700528-0molgkl9 authors: Barlow, Brooke; Barlow, Ashley; Thompson Bastin, Melissa L; Berger, Karen; Dixit, Deepali; Heavner, Mojdeh S title: Minimizing pharmacotherapy-related healthcare worker exposure to SARS-CoV-2 date: 2020-05-29 journal: Am J Health Syst Pharm DOI: 10.1093/ajhp/zxaa190 sha: 2388509e1bee2e574f1ca012c60ab37cdfb06ea8 doc_id: 700528 cord_uid: 0molgkl9 nan The coronavirus disease 2019 (COVID-19) pandemic has led to a healthcare crisis as clinicians seek to provide care for growing numbers of critically ill patients while trying to prevent selfexposure. Protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) requires personal protective equipment (PPE); however, demand for PPE has often exceeded what existing supply chains are able to provide. The Centers for Disease Control and Prevention has recommended use of alternative respiratory PPE and reuse of N95 masks as strategies to optimize supply. 1 Compromising optimal PPE standards may lead to increased infection among healthcare workers. CDC's Morbidity and Mortality Weekly Report of April 9, 2020, suggested that approximately 1 in 5 cases of COVID-19 had occurred in healthcare personnel, and 55% of these individuals reported exposure in a healthcare setting. 2 To protect frontline providers combating COVID-19, a multipronged approach to minimize direct patient exposure and conserve PPE is necessary. In this article, we provide a medication-focused perspective on strategies to mitigate health system-related SARS-CoV-2 infection risk to medical workers. The strategies we discuss include the use of medication administration bundles, extended tubing sets, conservative therapeutic drug monitoring, and maximally concentrated continuous infusions. An average of 25 medication doses are prescribed to a single hospitalized patient per day. Only 25% of these doses are scheduled at standardized administration times, leaving the remaining doses to be staggered at random intervals. 3 Lack of awareness regarding timing of medications can lead to interruptions in workflow and unnecessary direct patient contact. Creating medication bundles aimed at standardizing medication administration times to align with routine patient encounters can alleviate nursing staff task burden and healthcare worker exposure to SARS-CoV-2. This intervention should be personalized to each patient and requires collaboration with nursing personnel to coordinate medication administration with routine care activities such as turning the patient, vital sign assessments, and blood sampling for laboratory tests. A collaborative care team approach should be taken to prioritize the prescribing of medications and formulations dosed at the lowest frequency (eg, once daily as opposed to multiple times a day). For example, patients with COVID-19 without evidence of acute kidney injury can be administered low-molecular-weight heparin 1 or 2 times a day for venous Another key intervention to help ensure the safety of healthcare workers is minimizing prescribing of medications whose use requires therapeutic drug monitoring (TDM). Use of several antibiotics (eg, vancomycin, aminoglycosides), antiepileptics (eg, phenytoin, valproic acid) and anticoagulants (eg, unfractionated heparin, argatroban, bivalirudin) requires routine laboratory monitoring, increasing the need for direct patient contact to perform blood draws and infusion rate adjustments. Healthcare teams should have a collaborative discussion regarding transitioning appropriately selected patients from TDM-intensive medications to safe and effective alternatives, with therapy de-escalation when appropriate. For example, in a hospitalized patient with COVID-19 who is initiated on empiric broad-spectrum antibiotics, using linezolid as an alternative to vancomycin can eliminate the need for TDM. If vancomycin is deemed the most appropriate agent for empiric therapy, strategies for rapid de-escalation of therapy can include nasal screening for methicillin-resistant Staphylococcus aureus. As a laboratory stewardship strategy, vancomycin TDM can be restricted to patients who will require extended therapy or have rapidly changing renal function, and it can be avoided altogether in the empiric therapy setting. As always, a good policy is "think before you draw"; if the results of TDM will not change management decisions, blood sampling should be avoided. Inevitably, there may be instances when a TDM-requiring medication is warranted. In such circumstances, the simplest solution is to align blood draws with room entry for other required tasks at the bedside. Conclusion. SARS-CoV-2 is a highly contagious virus that has prompted escalating concerns of transmission to healthcare workers in the hospital setting. In order to minimize exposure risk, avoiding unnecessary contact with SARS-CoV-2-infected patients is critical. There are several opportunities to mitigate pharmacotherapy-related interruptions in workflow for healthcare professionals providing direct patient care to patients with COVID-19. Care teams, in coordination with the team pharmacist, should use a nimble approach to medication selection, use, and monitoring in this setting. Characteristics of health care personnel with COVID-19 -United States The nurse's medication day COVID-19 clinical considerations: using extra-long extension sets with the BD Alaris Pump Module and Alaris Syringe Module The authors have declared no potential conflicts of interest.